A group of researchers has developed and externally validated the first-ever predictive model to help clinicians identify ...
Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback